Medline (FRA:L10) Moat Score: 5/10 (As of Jun. 28, 2026)


FRA:L10 Medline Inc FRA:L10
14 GF Score
Price €32.60
! 3 Warning Signs
View Full Analysis

What is Medline Moat Score?

Medline FRA:L10 +5.16% 14 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates FRA:L10 with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Medline ranks better than 91.15% on this metric.

Medline has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Medline has Narrow Moat: Medline Inc benefits from a solid narrow moat due to its strong distribution network and moderate brand strength. It has some customer loyalty and economies of scale, but lacks significant intellectual property or regulatory barriers to ensure a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medline might have Narrow Moat - Solid narrow moat.

Medline  (FRA:L10) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medline Moat Score Related Terms

FRA:L10 vs RMD, WST, BDX: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Medline's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medline Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medline's Moat Score distribution charts can be found below:

* The bar in red indicates where Medline's Moat Score falls into.


FRA:L10
14GF Score
Medline Inc FRA:L10
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Medline (FRA:L10) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Medline ranks #75 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Medline's Moat Score too high?
Medline's current Moat Score is 5. Based on the distribution chart, Medline ranks #75 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medline has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Medline's Moat Score compare to RMD and WST?
According to the Medical Devices & Instruments industry distribution chart, Medline ranks #75 out of 847 companies for Moat Score. This places Medline in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Medline's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (FRA:L10) has a current Moat Score of 5. The current Moat Score is 5. Medline's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Medline (FRA:L10), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medline Business Description

Other Exchanges MDLN:USA
Address 3 Lakes Drive, Northfield, IL, USA, 60093
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
14GF Score

Get the complete analysis for FRA:L10

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.60
Price